Detalhe da pesquisa
1.
Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases.
Eur J Haematol
; 106(4): 493-499, 2021 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-33378569
2.
Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials.
Am J Hematol
; 96(8): E269-E272, 2021 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33878220
3.
TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases.
Am J Hematol
; 96(8): E306-E310, 2021 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33989438
4.
Radiation induced delayed transverse myelitis and neurological deficit at tertiary care center.
Ann Med Surg (Lond)
; 69: 102728, 2021 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-34457260
5.
An unusual case of T-cell acute lymphoblastic leukemia in a patient with BCR-ABL positive chronic myeloid leukemia and Gaucher disease.
Ann Med Surg (Lond)
; 68: 102565, 2021 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-34336196
6.
Spotlight on Melphalan Flufenamide: An Up-and-Coming Therapy for the Treatment of Myeloma.
Drug Des Devel Ther
; 15: 2969-2978, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34262262
7.
An in-depth evaluation of acalabrutinib for the treatment of mantle-cell lymphoma.
Expert Opin Pharmacother
; 21(1): 29-38, 2020 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-31738609
8.
TP53 dysfunction in chronic lymphocytic leukemia: clinical relevance in the era of B-cell receptors and BCL-2 inhibitors.
Expert Opin Investig Drugs
; 29(8): 869-880, 2020 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-32551999
9.
Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib-rituximab.
Blood Cancer J
; 10(9): 92, 2020 09 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-32938904